Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)
Status:
Completed
Trial end date:
2011-06-30
Target enrollment:
Participant gender:
Summary
This is a Phase IIIB, randomized, prospective, multicenter, single-country, open-label,
controlled pilot trial designed to evaluate the effect of infliximab induction therapy on
sustained virologic response (SVR) to treatment with pegylated interferon alfa-2b plus
ribavirin in a group of 96 therapy-naïve subjects with genotype 1 hepatitis C virus (HCV)
infection and high serum tumor necrosis factor (TNF)-alpha values.